Senomyx (NASDAQ: SNMX) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Senomyx to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, dividends, risk, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for Senomyx and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senomyx 0 3 0 0 2.00
Senomyx Competitors 471 2238 6133 118 2.66

Senomyx presently has a consensus target price of $2.00, indicating a potential upside of 143.22%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 1.08%. Given Senomyx’s higher probable upside, equities research analysts plainly believe Senomyx is more favorable than its rivals.

Profitability

This table compares Senomyx and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senomyx -63.38% -85.22% -54.58%
Senomyx Competitors -3,971.40% -118.78% -44.07%

Institutional and Insider Ownership

28.9% of Senomyx shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 12.4% of Senomyx shares are owned by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Senomyx and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Senomyx $19.56 million -$11.72 million -3.16
Senomyx Competitors $207.78 million -$2.31 million 0.49

Senomyx’s rivals have higher revenue and earnings than Senomyx. Senomyx is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Senomyx has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Senomyx’s rivals have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.

Summary

Senomyx rivals beat Senomyx on 9 of the 12 factors compared.

About Senomyx

Senomyx, Inc. is focused on using taste receptor technologies to discover, develop and commercialize flavor ingredients for the packaged food, beverage and ingredient supply industries. The Company operates through development and commercialization of flavor ingredients segment. It is engaged in the discovery, development and/or commercialization of flavor ingredients through over five programs. The Sweet Taste Program is focused on developing flavor ingredients or discovering natural sweeteners. The Savory Flavor Program is focused at flavor ingredients to be used in product categories, such as ready meals, sauces, soups and snack foods. The Bitter Blocker Program is focused on flavor ingredients used in products that contain bitter tastants. The Cooling Taste Program is focused at flavor ingredients used in products that consist of cooling agents. The salt taste modifier program is focused on reduction of the level of salt contained in packaged food and beverage products.

Receive News & Ratings for Senomyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senomyx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.